Select Page

South Delhi Pharma, New Delhi, India

DUPIXENT (dupilumab) injection. FDA-Approved. To treat Eczema

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

DUPIXENT (dupilumab) injection is a prescription medicine. DUPIXENT (dupilumab) injection is used to treat people aged 6 years and older with moderate-to-severe atopic dermatitis (eczema).
INDICATIONS AND USAGE
DUPIXENT is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.
DOSAGE FORMS & STRENGTHS
• Injection: 300 mg/2 mL solution in a single-dose pre-filled syringe with needle shield
• Injection: 300 mg/2 mL solution in a single-dose pre-filled syringe
Manufactured By: Regeneron
Prescribing Information URL: Click Here

South Delhi Pharma facilitate the supply of “DUPIXENT (dupilumab) injection FDA Approved” medication. Supplied under Named Patient Program to all locations in India and other part of countries. Anti-Cancer drugs is available upon request after fulfilling the legal requirement (if applicable). To get best price share your mobile number and email ID.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

9 + 6 =

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis.

Dupilumab appears to be useful for moderate-to-severe atopic dermatitis for which it is approved in the United States. It is also being evaluated for treatment of persistent asthma in adults and adolescents. In October 2019, the European Commission (EC) approved Dupixent in chronic rhinosinusitis with nasal polyposis (CRSwNP).

In September 2020, the FDA granted dupilumab breakthrough therapy status for the treatment of eosinophilic esophagitis.

Reviews

There are no reviews yet.

Be the first to review “DUPIXENT (dupilumab) injection. FDA-Approved. To treat Eczema”

Your email address will not be published.